23andme Holding Co (ME)

$0.5055

+0.15

(+41.91%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on 23andme Holding Co

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 92.37M → 44.74M (in $), with an average decrease of 20.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -75.27M → -277.97M (in $), with an average decrease of 269.3% per quarter

  • Vs IQV

    In the last 1 year, Iqvia Holdings Inc. has given 12.1% return, outperforming this stock by 94.8%

  • Vs TMO

    In the last 3 years, Thermo Fisher Scientific, Inc. has given 5.4% return, outperforming this stock by 101.8%

Performance

  • $0.44
    $0.61
    $0.51
    downward going graph

    14.69%

    Downside

    Day's Volatility :29.03%

    Upside

    16.82%

    downward going graph
  • $0.35
    $2.21
    $0.51
    downward going graph

    31.37%

    Downside

    52 Weeks Volatility :84.16%

    Upside

    76.92%

    downward going graph

Returns

Period23andme Holding CoSector (Health Care)Index (Russel 2000)
3 Months
-46.84%
-0.7%
0.0%
6 Months
-55.39%
6.6%
0.0%
1 Year
-82.71%
3.7%
-1.5%
3 Years
-96.41%
14.0%
-21.8%

Highlights

Market Capitalization
188.4M
Book Value
$0.78
Earnings Per Share (EPS)
-1.11
Wall Street Target Price
1.43
Profit Margin
-210.48%
Operating Margin TTM
-180.82%
Return On Assets TTM
-26.17%
Return On Equity TTM
-92.53%
Revenue TTM
248.0M
Revenue Per Share TTM
0.53
Quarterly Revenue Growth YOY
-33.2%
Gross Profit TTM
132.9M
EBITDA
-315.5M
Diluted Eps TTM
-1.11
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.1
EPS Estimate Next Year
-0.61
EPS Estimate Current Quarter
-0.14
EPS Estimate Next Quarter
-0.11

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for 23andme Holding Co(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 182.89%

Current $0.51
Target $1.43

Company Financials

FY19Y/Y Change
Revenue
440.9M
-
Net Income
-183.5M
-
Net Profit Margin
-41.63%
-
FY20Y/Y Change
Revenue
305.5M
↓ 30.72%
Net Income
-289.3M
↑ 57.63%
Net Profit Margin
-94.71%
↓ 53.08%
FY21Y/Y Change
Revenue
243.9M
↓ 20.15%
Net Income
-183.4M
↓ 36.62%
Net Profit Margin
-75.17%
↑ 19.54%
FY22Y/Y Change
Revenue
271.9M
↑ 11.47%
Net Income
-217.5M
↑ 18.61%
Net Profit Margin
-79.99%
↓ 4.82%
FY23Y/Y Change
Revenue
299.5M
↑ 10.15%
Net Income
-311.7M
↑ 43.3%
Net Profit Margin
-104.06%
↓ 24.07%
Q3 FY22Q/Q Change
Revenue
75.7M
↑ 17.28%
Net Income
-66.1M
↓ 26.21%
Net Profit Margin
-87.32%
↑ 51.46%
Q4 FY22Q/Q Change
Revenue
66.9M
↓ 11.52%
Net Income
-92.0M
↑ 39.2%
Net Profit Margin
-137.38%
↓ 50.06%
Q1 FY23Q/Q Change
Revenue
92.4M
↑ 38.0%
Net Income
-64.1M
↓ 30.3%
Net Profit Margin
-69.39%
↑ 67.99%
Q2 FY23Q/Q Change
Revenue
60.9M
↓ 34.11%
Net Income
-104.6M
↑ 63.23%
Net Profit Margin
-171.9%
↓ 102.51%
Q3 FY23Q/Q Change
Revenue
50.0M
↓ 17.85%
Net Income
-75.3M
↓ 28.06%
Net Profit Margin
-150.54%
↑ 21.36%
Q4 FY23Q/Q Change
Revenue
44.7M
↓ 10.5%
Net Income
-278.0M
↑ 269.31%
Net Profit Margin
-621.22%
↓ 470.68%
FY19Y/Y Change
Total Assets
696.7M
-
Total Liabilities
382.9M
-
FY20Y/Y Change
Total Assets
404.6M
↓ 41.92%
Total Liabilities
270.4M
↓ 29.37%
FY21Y/Y Change
Total Assets
452.1M
↑ 11.73%
Total Liabilities
1.0B
↑ 287.43%
FY22Y/Y Change
Total Assets
1.2B
↑ 154.83%
Total Liabilities
236.4M
↓ 77.44%
FY23Y/Y Change
Total Assets
942.6M
↓ 18.18%
Total Liabilities
228.7M
↓ 3.28%
Q3 FY22Q/Q Change
Total Assets
1.0B
↓ 2.02%
Total Liabilities
221.4M
↑ 6.43%
Q4 FY22Q/Q Change
Total Assets
1.0B
↓ 1.54%
Total Liabilities
273.7M
↑ 23.6%
Q1 FY23Q/Q Change
Total Assets
942.6M
↓ 8.01%
Total Liabilities
228.7M
↓ 16.44%
Q2 FY23Q/Q Change
Total Assets
871.2M
↓ 7.57%
Total Liabilities
195.7M
↓ 14.41%
Q3 FY23Q/Q Change
Total Assets
801.2M
↓ 8.03%
Total Liabilities
176.0M
↓ 10.08%
Q4 FY23Q/Q Change
Total Assets
608.2M
↓ 24.09%
Total Liabilities
231.0M
↑ 31.28%
FY19Y/Y Change
Operating Cash Flow
-98.1M
-
Investing Cash Flow
-27.8M
-
Financing Cash Flow
344.4M
-
FY20Y/Y Change
Operating Cash Flow
-185.8M
↑ 89.33%
Investing Cash Flow
-72.8M
↑ 161.58%
Financing Cash Flow
8.8M
↓ 97.44%
FY21Y/Y Change
Operating Cash Flow
-74.3M
↓ 60.03%
Investing Cash Flow
-6.5M
↓ 91.02%
Financing Cash Flow
155.3M
↑ 1659.17%
FY22Y/Y Change
Operating Cash Flow
-166.8M
↑ 124.68%
Investing Cash Flow
-108.1M
↑ 1554.48%
Financing Cash Flow
546.0M
↑ 251.5%
FY23Y/Y Change
Operating Cash Flow
-165.4M
↓ 0.86%
Investing Cash Flow
-11.3M
↓ 89.55%
Financing Cash Flow
9.8M
↓ 98.21%
Q3 FY22Q/Q Change
Operating Cash Flow
-72.9M
↓ 0.15%
Investing Cash Flow
-2.1M
↓ 29.28%
Financing Cash Flow
5.6M
↑ 268.49%
Q4 FY22Q/Q Change
Operating Cash Flow
25.5M
↓ 135.02%
Investing Cash Flow
-3.1M
↑ 49.49%
Financing Cash Flow
-11.0K
↓ 100.19%
Q1 FY23Q/Q Change
Operating Cash Flow
-45.0M
↓ 276.01%
Investing Cash Flow
-3.3M
↑ 7.24%
Financing Cash Flow
2.6M
↓ 23790.91%
Q2 FY23Q/Q Change
Operating Cash Flow
-69.4M
↑ 54.26%
Investing Cash Flow
-2.7M
↓ 18.04%
Financing Cash Flow
-114.0K
↓ 104.37%

Technicals Summary

Sell

Neutral

Buy

23andme Holding Co is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
23andme Holding Co
23andme Holding Co
-24.36%
-55.39%
-82.71%
-96.41%
-96.37%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-9.73%
12.44%
-0.8%
-9.52%
118.88%
Agilent Technologies Inc.
Agilent Technologies Inc.
-7.9%
23.88%
-3.2%
0.79%
76.64%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-5.65%
17.12%
-6.43%
12.22%
110.66%
Danaher Corp.
Danaher Corp.
-4.8%
16.89%
-6.54%
-1.07%
88.84%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-10.49%
20.27%
12.09%
5.1%
70.85%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
23andme Holding Co
23andme Holding Co
NA
NA
NA
-1.1
-0.93
-0.26
NA
0.78
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
48.76
48.76
4.75
11.13
0.81
0.23
NA
17.88
Agilent Technologies Inc.
Agilent Technologies Inc.
33.53
33.53
2.7
5.5
0.21
0.08
0.01
21.12
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
35.85
35.85
2.81
21.56
0.13
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
42.54
42.54
3.13
7.62
0.08
0.04
0.0
72.36
Iqvia Holdings Inc.
Iqvia Holdings Inc.
31.74
31.74
1.33
11.11
0.23
0.05
NA
33.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
23andme Holding Co
23andme Holding Co
Buy
$188.4M
-96.37%
NA
-210.48%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$40.7B
118.88%
48.76
23.08%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$41.1B
76.64%
33.53
18.35%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$211.7B
110.66%
35.85
13.99%
Danaher Corp.
Danaher Corp.
Buy
$178.0B
88.84%
42.54
19.94%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.1B
70.85%
31.74
9.06%

Institutional Holdings

  • Vanguard Group Inc

    4.89%

  • BlackRock Inc

    4.87%

  • NewView Capital Partners I, LLC

    4.22%

  • Euclidean Capital LLC

    2.22%

  • Geode Capital Management, LLC

    1.53%

  • State Street Corporation

    1.24%

Corporate Announcements

  • 23andme Holding Co Earnings

    23andme Holding Co’s price-to-earnings ratio stands at None

    Read More

Company Information

23andme is the leading personal genetics company dedicated to helping individuals understand their own genetic information through dna analysis technologies and web-based interactive tools. the company's personal genome service® enables individuals to gain deeper insights into their ancestry and genetic make-up. the vision for 23andme is to personalize healthcare by making and supporting meaningful discoveries through genetic research. 23andme was founded in 2006, and the company is advised by a group of renowned experts in the fields of human genetics, bioinformatics and computer science.

Organization
23andme Holding Co
Employees
769
CEO
Ms. Anne Wojcicki
Industry
Healthcare

Discover More

FAQs